Friday - April 18, 2025
ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its relationship with an existing eValuator client include the recently released eValuator Quality Module. Streamline expects that this module will increase the SaaS revenues from its eValuator relationship with this client by 25%.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-powered pre-bill code auditing analyzes 100% of encounters in real-time, ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials. The eValuator quality module enables health systems to prospectively assess the risk score of individual claims and their estimated impact on overall quality measurement in real time. By eliminating manual, post-hoc risk scoring practices, the quality module introduces an industry-leading workflow that allows for correction of coding errors signaled by risk scores.
“We are thrilled to provide additional value to our existing eValuator client by supporting their efforts to better understand the quality of care they’ve provided,” stated Ben Stilwill, President and Chief Executive Officer, Streamline.
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Last Trade: | US$2.33 |
Daily Change: | 0.02 0.87 |
Daily Volume: | 7,688 |
Market Cap: | US$9.950M |
January 22, 2025 December 18, 2024 December 16, 2024 October 08, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load